menu
    • menu
    [{"orgOrder":0,"company":"InflaRx","sponsor":"Staidson Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"BDB-001","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Staidson Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Staidson Biopharma"},{"orgOrder":0,"company":"Staidson Biopharma","sponsor":"Pivotal Bioventure Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"BDB-001","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Staidson Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Staidson Biopharma \/ Pivotal Bioventure Partners","highestDevelopmentStatusID":"8","companyTruncated":"Staidson Biopharma \/ Pivotal Bioventure Partners"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Beijing Defengrei Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrei Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrei Biotechnology"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Beijing Defengrei Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrei Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrei Biotechnology"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Beijing Defengrui Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrui Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrui Biotechnology"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Beijing Defengrui Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrui Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrui Biotechnology"},{"orgOrder":0,"company":"Seven and Eight Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Oncology","graph2":"Phase I","graph3":"Seven and Eight Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seven and Eight Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Seven and Eight Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Oncology","graph2":"Phase II","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eikon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Oncology","graph2":"Phase II","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Eikon Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Seven and Eight","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Oncology","graph2":"Phase II","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikon Therapeutics \/ Seven and Eight","highestDevelopmentStatusID":"8","companyTruncated":"Eikon Therapeutics \/ Seven and Eight"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Immunology","graph2":"Phase III","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"J.P. Morgan | Morgan Stanley | BofA Securities | Cantor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2026","type":"Public Offering","leadProduct":"Resiquimod Sulfate","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Eikon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eikon Therapeutics \/ J.P. Morgan | Morgan Stanley | BofA Securities | Cantor","highestDevelopmentStatusID":"9","companyTruncated":"Eikon Therapeutics \/ J.P. Morgan | Morgan Stanley | BofA Securities | Cantor"}]

    Find Clinical Drug Pipeline Developments & Deals for Resiquimod Sulfate

    Menu

    Resiquimod Sulfate

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eikon Therapeutics

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod Sulfate,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : J.P. Morgan | Morgan Stanley | BofA Securities | Cantor

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Eikon Plans IPO for Clinical Cancer Drugs

                            Details : The proceeds from the offering will be used to fund the clinical development of Resiquimod Sulfate for targeting Toll-like-7/Toll-like-8 receptors in advanced melanoma.

                            Product Name : EIK1001

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 12, 2026

                            Lead Product(s) : Resiquimod Sulfate,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : J.P. Morgan | Morgan Stanley | BofA Securities | Cantor

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod Sulfate,Cyclophosphamide,Rituximab,Azathioprine

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BDB-001 Phase III Trial in ANCA-Associated Vasculitis

                            Details : BDB001 is a Cell & Gene Therapy drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of ANCA-associated with Vasculitis.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 11, 2025

                            Lead Product(s) : Resiquimod Sulfate,Cyclophosphamide,Rituximab,Azathioprine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            InflaRx

                            Germany arrow
                            Pharmapack
                            Not Confirmed

                            InflaRx

                            Germany arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Staidson Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connec...

                            Details : Under the co-development agreement, BDB-001, an anti-C5a antibody that originated from the same cell line as vilobelimab, is being developed by STS for the treatment of severe COVID-19 and other inflammatory diseases in China.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 21, 2022

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Staidson Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Beijing Defengrei Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability of BDB-001 Injection in Healthy Subjects

                            Details : BDB001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 04, 2022

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Beijing Defengrei Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Beijing Defengrei Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tolerability and Safety of BDB-001 Injection in Healthy Subjects

                            Details : BDB001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 04, 2022

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Beijing Defengrei Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod Sulfate,Cyclophosphamide,Glucocorticoid

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil C...

                            Details : BDB001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 20, 2022

                            Lead Product(s) : Resiquimod Sulfate,Cyclophosphamide,Glucocorticoid

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (H...

                            Details : BDB001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hidradenitis Suppurativa.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 02, 2021

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (H...

                            Details : BDB001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hidradenitis Suppurativa.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 26, 2021

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed

                            Staidson (Beijing) Biopharmaceuticals Co., Ltd

                            Country arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Beijing Defengrui Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

                            Details : BDB001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 12, 2021

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Beijing Defengrui Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Eikon Therapeutics

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            Pharmapack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

                            Details : BDB001 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 29, 2021

                            Lead Product(s) : Resiquimod Sulfate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.